# MediMind — Clinical Review Packet: Chief Medical Officer (CMO) Sign-Off

**Document Version:** 1.0.0  
**Target Reviewer:** Chief Medical Officer (CMO) & Clinical AI Governance Board  
**Governance Scope:** Stage 2 Diabetes Prospective Shadow Evaluation Protocol & Threshold Predeclaration  
**Current Approval Status:** **`PENDING CLINICAL APPROVAL`**  
**Review Target Date:** October 2026  
**Repository:** `D:\projects\MediMind`  

---

## 1. Executive Purpose & Clinical Context

This review packet is submitted to the Chief Medical Officer to evaluate and authorize the clinical evaluation protocol for two candidate AI models for adult Type 2 Diabetes risk screening:
1. **Candidate C:** `appC_mlp_6layer_bottleneck_gelu` (Deep PyTorch 6-Layer Bottleneck MLP, GELU activation).
2. **Candidate A:** `appA_extratrees` (Calibrated Extra-Trees ensemble).

> [!IMPORTANT]
> **Safety Invariant:** In shadow evaluation mode, candidate models generate predictions silently in an isolated error boundary. Their outputs are never displayed to clinicians, never returned to patients, and never written to canonical medical records. The existing production model remains the sole serving model.

---

## 2. Clinical Risk Analysis

| Clinical Risk Category | Potential Impact | Engineering & Operational Mitigation |
| :--- | :--- | :--- |
| **Under-Triage (False Negatives)** | A diabetic or pre-diabetic patient receives an erroneously low risk score, delaying clinical lifestyle intervention or lab testing. | Predeclared Sensitivity Gate of $\ge 75.0\%$ for Candidate C and $\ge 70.0\%$ for Candidate A; operating threshold set at $t = 0.4000$ yields $87.80\%$ test sensitivity (only $5/41$ cases missed on held-out test data). |
| **Alarm Fatigue (False Positives)** | Over-flagging healthy patients generates unnecessary confirmatory HbA1c testing and patient anxiety. | Predeclared Specificity Gate of $\ge 70.0\%$ (Candidate C) and $\ge 75.0\%$ (Candidate A); Extra-Trees candidate achieves $76.0\%$ test specificity ($24\%$ false-positive rate). |
| **Calibration Misrepresentation** | A clinician misinterprets a raw risk probability score because the model is over- or under-confident. | Evaluated via 10-bin Equal-Width ECE. Candidate C achieves exceptional calibration ($\text{ECE} = 0.0291$, Brier score $0.1665$) without post-hoc calibrators. |
| **Demographic / Age Bias** | Disparate predictive sensitivity across younger ($<50$) vs older ($\ge 50$) patients. | Predeclared Subgroup Disparity Gate: Sensitivity Disparity Ratio $\ge 0.80$ across age cohorts. |

---

## 3. Available Technical Evidence & Metric Summary

Evaluated on held-out stratified test cohort ($N = 116$, 41 diabetic, 75 non-diabetic):

```
                        Sensitivity      Specificity     Test ROC-AUC     Test ECE       P95 Latency
Candidate C (MLP, t=0.40)  87.80% (36/41)   64.00% (48/75)   0.8387          0.0291          9.09 ms
Candidate C (MLP, t=0.45)  85.37% (35/41)   65.33% (49/75)   0.8387          0.0291          9.09 ms
Candidate A (Trees, t=0.43) 85.37% (35/41)   76.00% (57/75)   0.8634          0.1374         140.14 ms
Production Baseline (t=0.50) 68.29% (28/41)   78.67% (59/75)   0.8012          0.0894          4.20 ms
```

---

## 4. Key Decisions Required from the CMO

1. **Predeclared Operating Threshold:**
   - [ ] **Option 1 (Recommended):** Approve $t = 0.4000$ for Candidate C (maximizes clinical sensitivity at $87.80\%$, missed cases $5/41$).
   - [ ] **Option 2:** Approve conservative $t = 0.4500$ (Sensitivity $85.37\%$, Specificity $65.33\%$).
2. **Cohort Eligibility & Exclusion Criteria:**
   - Confirm mandatory exclusion of pediatric patients ($<18$ years of age).
   - Confirm mandatory exclusion of active pregnancy / gestational diabetes screenings.
   - Confirm exclusion of acute inpatient / emergency admissions (ICU, DKA, sepsis).
3. **Evaluation Window & Sample Volume:**
   - Approve prospective duration: 30 consecutive calendar days, with automatic extension to 60 days if fewer than 500 eligible encounters are collected.
   - Confirm minimum target: 500 eligible prospective adult outpatient encounters.

---

## 5. Formal Clinical Sign-Off

| Review Dimension | Decision | Comments / Notes | Sign-off Date |
| :--- | :--- | :--- | :--- |
| **Clinical Protocol Authorization** | **`PENDING`** | *Awaiting CMO formal signature* | Pending |
| **Candidate C Operating Threshold** | **`PENDING`** | *Awaiting selection: t=0.40 vs t=0.45* | Pending |
| **Predeclared Validation Gates** | **`PENDING`** | *Awaiting governance board sign-off* | Pending |

**Designated Approver:** Chief Medical Officer (CMO), MediMind Healthcare Platform  
**Signature:** `________________________________________`  
**Date:** `____ / ____ / 2026`
